Hikma Buys Teligent Assets To Expand Into Canada
Deal Worth $46m For Canadian Sterile Injectable Assets Follows Teligent Bankruptcy
Executive Summary
Hikma has snapped up the Canadian sterile injectables assets of bankrupt Teligent in a $46m deal that marks Hikma’s first move into Canada.
You may also be interested in...
Hikma Expectations Stabilize – But Generics Still Set To Take A Hit
After multiple cuts to its Generics guidance earlier this year, Hikma has reiterated its expectations for the company’s full-year results, citing momentum for the firm’s Injectables and Branded segments as well as promising that growth is on the horizon for Generics in 2023.
Hikma Will Push Harder To Make M&A Happen
Following a challenging first half for Hikma, executive chairman and CEO Said Darwazah talks to Generics Bulletin about how the firm is planning to be more active in making deals happen, as well as how it plans to address pressures on its Generics division that led to two consecutive downgrades in guidance this year.
Hikma Has An Appetite For More Deals As It Builds On Acquisitions
Hikma has the financial firepower and appetite to maintain its current deal-making momentum following several key transactions over the past year, CEO Siggi Olafsson tells Generics Bulletin in the first part of an exclusive interview, while also detailing how the firm plans to build up its US biosimilars business.